Abstracts tagged "synovium and signal transduction"

Abstract Number: 1412 • 2017 ACR/ARHP Annual Meeting
Yra-1909 suppresses Production of Pro-Inflammatory Mediators and MMPs through Downregulating Akt, p38, JNK and NF-κb Activation in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Hyun Jung Yoo^1,2, Jeong Yeon Kim¹, Shin Eui Kang¹, Ji Seok Yoo³, Yong Nam Lee³, Dong Goo Lee³, Ji Soo Park¹, Eun Bong Lee⁴, Eun Young Lee⁴ and Yeong Wook Song^2,5, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Korea, Republic of (South), ³Central R&D Institute, Yungjin Pharm Co., Ltd., Suwon, Korea, Suwon, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Rheumatoid arthritis (RA) is characterized by hyperplastic synovial pannus tissue, which mediates destruction of cartilage and bone. Fibroblast-like synoviocyte (FLS) are a key component…
Abstract Number: 2525 • 2012 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase Inhibition Suppresses Inflammatory Cytokine Production and Affects Gene Expression in Human Macrophages and RA Synovial Tissue Explants
Linda M. Hartkamp¹, Inge E. van Es¹, Jay S. Fine², Michael Smith², John Woods², Satwant Narula³, Julie DeMartino², Paul P. Tak⁴ and Kris A. Reedquist¹, ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Inflammation Discovery, Hoffmann-La Roche, Nutley, NJ, ³Inflammatory Discovery, Hoffmann-La Roche, Nutley, NJ, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and progressive autoinflammatory disorder characterized by the infiltration of inflammatory cells, including B-cells, T-cells and macrophages, in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].